Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is an alloimmune disorder of pregnancy that results when the pregnant person’s immune system attacks fetal or newborn platelets, resulting in thrombocytopenia and risk of bleeding, which can be life-threatening.
FNAIT has an estimated incidence of 1 in 1000 pregnancies and is characterized by bleeding in a fetus’ major organs, such as the brain, gastrointestinal tract, lungs or eyes, and may result in lifelong disability or death. If a severe bleed occurs in the brain, it is termed intracranial hemorrhage (ICH), which can cause death or life-long effects. ICH occurs in up to 26 percent of babies in untreated pregnancies with FNAIT.
Families around the world need effective and targeted therapies with a demonstrated safety profiles that can potentially help address the serious health consequences of FNAIT. Many FNAIT cases are not properly diagnosed and there is no currently approved treatment. While conventional interventions like IVIG can help to increase the chance of fetal and infant survival, there remains an immense need for newer approved treatments with demonstrated safety profiles.
Fetal and neonatal alloimmune thrombocytopenia has an estimated incidence of 1 in 1000 pregnancies.”
J&J’s approach to fetal and neonatal alloimmune thrombocytopenia (FNAIT)
Johnson & Johnson is advancing understanding of alloantibody-driven conditions, including FNAIT, and studying an investigational treatment that could potentially block the placental transport of Immunoglobulin G (IgG) alloantibodies in pregnant adults to their babies.
